vs
Amneal Pharmaceuticals, Inc.（AMRX）与Circle Internet Group, Inc.（CRCL）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是Circle Internet Group, Inc.的1.1倍（$814.3M vs $739.8M），Circle Internet Group, Inc.净利率更高（29.0% vs 4.3%，领先24.7%），Circle Internet Group, Inc.同比增速更快（5113.5% vs 11.5%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $-14.7M）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Circle是2013年由杰里米·阿莱尔与肖恩·内维尔联合创立的支付科技企业，目前总部位于美国纽约，核心业务覆盖稳定币发行，推出了锚定美元的USDC、锚定欧元的EURC两款稳定币，同时还发行有代币化货币市场基金产品USYC。
AMRX vs CRCL — 直观对比
营收规模更大
AMRX
是对方的1.1倍
$739.8M
营收增速更快
CRCL
高出5102.1%
11.5%
净利率更高
CRCL
高出24.7%
4.3%
自由现金流更多
AMRX
多$123.3M
$-14.7M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $739.8M |
| 净利润 | $35.1M | $214.4M |
| 毛利率 | 36.5% | — |
| 营业利润率 | 13.8% | 11.0% |
| 净利率 | 4.3% | 29.0% |
| 营收同比 | 11.5% | 5113.5% |
| 净利润同比 | 212.9% | 202.0% |
| 每股收益（稀释后） | $0.10 | $0.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXCRCL
| Q4 25 | $814.3M | — | ||
| Q3 25 | $784.5M | $739.8M | ||
| Q2 25 | $724.5M | $658.1M | ||
| Q1 25 | $695.4M | — | ||
| Q4 24 | $730.5M | — | ||
| Q3 24 | $702.5M | — | ||
| Q2 24 | $701.8M | $6.8M | ||
| Q1 24 | $659.2M | — |
净利润AMRXCRCL
| Q4 25 | $35.1M | — | ||
| Q3 25 | $2.4M | $214.4M | ||
| Q2 25 | $22.4M | $-482.1M | ||
| Q1 25 | $12.2M | — | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-156.0K | — | ||
| Q2 24 | $6.0M | $32.9M | ||
| Q1 24 | $-91.6M | — |
毛利率AMRXCRCL
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
营业利润率AMRXCRCL
| Q4 25 | 13.8% | — | ||
| Q3 25 | 9.0% | 11.0% | ||
| Q2 25 | 15.4% | -49.5% | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 13.6% | — | ||
| Q1 24 | -1.6% | — |
净利率AMRXCRCL
| Q4 25 | 4.3% | — | ||
| Q3 25 | 0.3% | 29.0% | ||
| Q2 25 | 3.1% | -73.3% | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | -0.0% | — | ||
| Q2 24 | 0.9% | 486.5% | ||
| Q1 24 | -13.9% | — |
每股收益（稀释后）AMRXCRCL
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.01 | $0.64 | ||
| Q2 25 | $0.07 | $-4.48 | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $0.02 | $0.00 | ||
| Q1 24 | $-0.30 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $1.3B |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $3.0B |
| 总资产 | $3.7B | $76.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXCRCL
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | $1.3B | ||
| Q2 25 | $71.5M | $1.1B | ||
| Q1 25 | $59.2M | — | ||
| Q4 24 | $110.6M | — | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | $457.5M | ||
| Q1 24 | $46.5M | — |
总债务AMRXCRCL
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXCRCL
| Q4 25 | $-70.8M | — | ||
| Q3 25 | $-109.5M | $3.0B | ||
| Q2 25 | $-112.1M | $2.4B | ||
| Q1 25 | $-131.7M | — | ||
| Q4 24 | $-109.3M | — | ||
| Q3 24 | $-93.4M | — | ||
| Q2 24 | $-57.5M | $460.9M | ||
| Q1 24 | $-63.7M | — |
总资产AMRXCRCL
| Q4 25 | $3.7B | — | ||
| Q3 25 | $3.6B | $76.8B | ||
| Q2 25 | $3.4B | $64.2B | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.5B | — | ||
| Q2 24 | $3.5B | — | ||
| Q1 24 | $3.5B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $-10.7M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $-14.7M |
| 自由现金流率自由现金流/营收 | 13.3% | -2.0% |
| 资本支出强度资本支出/营收 | 2.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.72× | -0.05× |
| 过去12个月自由现金流最近4个季度 | $269.9M | — |
8季度趋势，按日历期对齐
经营现金流AMRXCRCL
| Q4 25 | $130.3M | — | ||
| Q3 25 | $118.5M | $-10.7M | ||
| Q2 25 | $83.8M | $303.7M | ||
| Q1 25 | $7.4M | — | ||
| Q4 24 | $118.1M | — | ||
| Q3 24 | $141.8M | — | ||
| Q2 24 | $39.7M | — | ||
| Q1 24 | $-4.4M | — |
自由现金流AMRXCRCL
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | $-14.7M | ||
| Q2 25 | $61.0M | $296.3M | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — | ||
| Q1 24 | $-13.6M | — |
自由现金流率AMRXCRCL
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | -2.0% | ||
| Q2 25 | 8.4% | 45.0% | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | -2.1% | — |
资本支出强度AMRXCRCL
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | 0.5% | ||
| Q2 25 | 3.2% | 1.1% | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.4% | — |
现金转化率AMRXCRCL
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | -0.05× | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
CRCL
暂无分部数据
